id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-E-0436-0007,FDA,FDA-2006-E-0436,"Certificate Extending Patent Term from U.S. Patent and Trademark Office to Cubist Pharmaceuticals, Inc.",Rule,Certificate Extending Patent Term,2007-10-23T04:00:00Z,2007,10,,,2025-12-17T10:00:23Z,,0,0,0900006480461d88
FDA-2006-E-0436-0006,FDA,FDA-2006-E-0436,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-01-11T05:00:00Z,2007,1,,,2025-12-16T21:53:35Z,,0,0,0900006480461d87
FDA-2006-E-0436-0005,FDA,FDA-2006-E-0436,Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN,Notice,General Notice,2006-06-14T04:00:00Z,2006,6,2006-06-14T04:00:00Z,,2025-12-16T21:50:04Z,E6-9225,0,0,0900006480461d84
FDA-2006-E-0436-0004,FDA,FDA-2006-E-0436,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-05-24T04:00:00Z,2006,5,,,2025-12-16T21:38:51Z,,0,0,0900006480461d81
FDA-2006-E-0436-0003,FDA,FDA-2006-E-0436,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-05-23T04:00:00Z,2006,5,,,2025-12-16T21:35:14Z,,0,0,0900006480461d80
FDA-2006-E-0436-0002,FDA,FDA-2006-E-0436,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-02-27T05:00:00Z,2006,2,,,2025-12-16T20:58:21Z,,0,0,0900006480461d7a
FDA-2006-E-0436-0001,FDA,FDA-2006-E-0436,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-01-20T05:00:00Z,2006,1,,,2025-12-16T20:48:18Z,,0,0,0900006480461d5a